Mesoblast to Host R&D Day on April 8, 2026

Core Insights - Mesoblast Limited will host its inaugural R&D Day on April 8, 2026, in New York City, featuring presentations from senior leadership and key opinion leaders [1][2] - The event will discuss the company's corporate strategy, the commercialization of its flagship product Ryoncil, and its multi-billion-dollar pipeline opportunities in inflammatory pain and cardiovascular disease [2][3] Company Overview - Mesoblast is a global leader in developing allogeneic cellular medicines for severe inflammatory conditions, utilizing a proprietary mesenchymal lineage cell therapy technology platform [3][5] - The company has a strong intellectual property portfolio with over 1,000 granted patents or applications, providing commercial protection until at least 2044 in major markets [6] Product Information - Ryoncil (remestemcel-L-rknd) is the first FDA-approved mesenchymal stromal cell therapy for treating steroid-refractory acute graft versus host disease in pediatric patients aged 2 months and older [4] - The company is developing additional therapies based on its technology platforms, targeting conditions such as heart failure and chronic low back pain [5] Manufacturing and Distribution - Mesoblast's proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf cellular medicines, which are planned to be readily available to patients worldwide [7] - The company has established commercial partnerships in Japan, Europe, and China to enhance its market reach [5]